Smithfield Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Smithfield Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60K	Hold	1,795	–	–	﹤0.01%	581
2026 Q1	$54K	Hold	1,795	–	–	﹤0.01%	584
2025 Q4	$56K	Buy	1,795 +36	+2%	+$887	﹤0.01%	564
2025 Q3	$35K	Hold	1,759	–	–	﹤0.01%	638
2025 Q2	$30K	Hold	1,759	–	–	﹤0.01%	651
2025 Q1	$27K	Sell	1,759 -980	-36%	-$17.5K	﹤0.01%	656
2024 Q4	$61K	Hold	2,739	–	–	﹤0.01%	530
2024 Q3	$50K	Buy	2,739 +980	+56%	+$17.2K	﹤0.01%	559
2024 Q2	$29K	Hold	1,759	–	–	﹤0.01%	622
2024 Q1	$25K	Hold	1,759	–	–	﹤0.01%	669
2023 Q4	$19K	Hold	1,759	–	–	﹤0.01%	717
2023 Q3	$18K	Hold	1,759	–	–	﹤0.01%	702
2023 Q2	$13K	Hold	1,759	–	–	﹤0.01%	782
2023 Q1	$15K	Hold	1,759	–	–	﹤0.01%	720
2022 Q4	$16K	Hold	1,759	–	–	﹤0.01%	694
2022 Q3	$14K	Hold	1,759	–	–	﹤0.01%	709
2022 Q2	$13K	Hold	1,759	–	–	﹤0.01%	764
2022 Q1	$16K	Hold	1,759	–	–	﹤0.01%	745
2021 Q4	$14K	Hold	1,759	–	–	﹤0.01%	783
2021 Q3	$18K	Hold	1,759	–	–	﹤0.01%	730
2021 Q2	$18K	Hold	1,759	–	–	﹤0.01%	721
2021 Q1	$20K	Hold	1,759	–	–	﹤0.01%	703
2020 Q4	$17K	Hold	1,759	–	–	﹤0.01%	705
2020 Q3	$16K	Hold	1,759	–	–	﹤0.01%	676
2020 Q2	$22K	Hold	1,759	–	–	﹤0.01%	612
2020 Q1	$16K	Hold	1,759	–	–	﹤0.01%	612
2019 Q4	$17K	Hold	1,759	–	–	﹤0.01%	642
2019 Q3	$12K	Hold	1,759	–	–	﹤0.01%	718
2019 Q2	$16K	Hold	1,759	–	–	﹤0.01%	662
2019 Q1	$28K	Hold	1,759	–	–	﹤0.01%	559
2018 Q4	$27K	Hold	1,759	–	–	﹤0.01%	551
2018 Q3	$38K	Hold	1,759	–	–	﹤0.01%	564
2018 Q2	$43K	Hold	1,759	–	–	0.01%	549
2018 Q1	$30K	Hold	1,759	–	–	﹤0.01%	587
2017 Q4	$33K	Hold	1,759	–	–	﹤0.01%	592
2017 Q3	$31K	Hold	1,759	–	–	﹤0.01%	595
2017 Q2	$58K	Sell	1,759 -20	-1%	-$619	0.01%	503
2017 Q1	$57K	Buy	1,779 +20	+1%	+$683	0.01%	499
2016 Q4	$64K	Buy	1,759 +1,350	+330%	+$53.9K	0.01%	469
2016 Q3	$19K	Sell	409 -200	-33%	-$10.4K	﹤0.01%	638
2016 Q2	$31K	Hold	609	–	–	0.01%	560
2016 Q1	$33K	Sell	609 -496	-45%	-$29.1K	0.01%	548
2015 Q4	$73K	Hold	1,105	–	–	0.02%	436
2015 Q3	$62K	Sell	1,105 -1,425	-56%	-$92.4K	0.01%	457
2015 Q2	$149K	Buy	2,530 +1,186	+88%	+$73.2K	0.03%	328
2015 Q1	$84K	Hold	1,344	–	–	0.02%	436
2014 Q4	$77K	Sell	1,344 -1,700	-56%	-$94.7K	0.02%	440
2014 Q3	$164K	Sell	3,044 -155	-5%	-$8.21K	0.03%	337
2014 Q2	$168K	Hold	3,199	–	–	0.03%	374
2014 Q1	$169K	Sell	3,199 -1,580	-33%	-$73K	0.03%	382
2013 Q4	$191K	Buy	4,779 +210	+5%	+$8.27K	0.04%	343
2013 Q3	$173K	Buy	4,569 +4,210	+1,173%	+$164K	0.04%	342
2013 Q2	$14K	Buy	+359	New	+$14K	﹤0.01%	611

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Smithfield Trust's TEVA Position: Q2 2026 in Review

Smithfield Trust held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 1,795 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #581.

Smithfield Trust first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $191K in Q4 2013. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Smithfield Trust held 1,795 shares of Teva Pharmaceuticals worth $60K as of Q2 2026.
Smithfield Trust left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Smithfield Trust's portfolio in Q2 2026, its #581 holding.
Smithfield Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Smithfield Trust's Teva Pharmaceuticals position peaked at $191K in Q4 2013.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.